Tenofovir disoproxil for the treatment of chronic hepatitis B

  • Technology appraisal guidance
  • TA173
  • Published: 
Download guidance (PDF)

1 Recommendations

This guidance does not apply to people with chronic hepatitis B who also have hepatitis C, hepatitis D or HIV.

1.1

Tenofovir disoproxil, within its marketing authorisation, is recommended as an option for the treatment of people with chronic HBeAg-positive or HBeAg-negative hepatitis B in whom antiviral treatment is indicated.